Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
  • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
  • C07D241/52—Oxygen atoms

Definitions

• R R and R are as above defined.
• the present invention is concerned with 2-halomethyl- B-carboxylic acid-amido-quinoxaline-l,4-di-N-oxides and their production. More particularly, these compounds can be represented by the formula:
• R is hydrogen, lower alkyl, lower alkoxy or chlorine
• R is hydrogen, straight or branched chain alkyl or straight or branched chain alkyl substituted by hydroxy, lower alkoxy, acyloxy, monoalkylamino or dialkylamino,
• R is hydrogen, straight or branched chain alkyl, straight or branched chain alkyl substituted by hydroxy, lower alkoxy, acyloxy, monoalkylamino or dialkylamino, or when R is hydrogen, cyclohexyl, or R and R together with the amide nitrogen atom form part of a 5- or 6-membered heterocyclic ring, and Hal is chlorine or bromine.
• the compounds of the present invention may be produced, inter alia, by halogenating a 2-methyl-3-carboxylic acid amido-quinoxaline-1,4-di-N-oxide of the formula:
• the preferred lower alkyl and lower alkoxy groups for R are those containing 1 to 4 carbon atoms.
• R and R are alkyl, it is preferred that the alkyl moieties contain 1 to 12 carbon atoms. Particularly preferred embodiments are those wherein the alkyl groups contain from 1 to 6 carbon atoms.
• the alkyl moieties of R and R are substituted by lower alkoxy, acyloxy, monoor dialkylamino moieties, it is preferred that the alkyl portions of those moieties contain from 1 to 4 carbon atoms. In the case of the dialkylamino moieties, each alkyl group is preferred to contain 1 to 4 carbon atoms.
• R and R together with the amide nitrogen atom form a part of a heterocyclic ring
• such a ring may contain, besides the amide nitrogen atom, and additional nitrogen atom or an oxygen heteroatom.
• the second heteroatom is preferably in the para position to the amide nitrogen atom and the hydrogen atom may be substituted on the additional nitrogen atom if nitrogen is the second heteroatom by lower alkyl of 1 to 4 carbon atoms which, in turn, may itself be substituted by hydroxy, methoxy or acetoxy.
• reaction of the invention can be represented by the following reaction mechanism:
• the Z-methyl-B-carboxylic acid amido-quinoxaline-l,4- di-N-oxides of Formula II may be obtained by reaction of *benzofuroxanes and acetoacetic acid amides or acetoacetic acid phenyl ester with ammonia or primary amines.
• German application F53665 IVd/ 12p filed Oct. 4, 1967 and corresponding United States application filed concurrently herewith and designated Le A 11052-A Ser. No. 764,611 filed Oct. 2, 1968 disclose methods for pro ducing compound II.
• Z-methyl-quinoxaline-di-N-oxides which can be used according to the invention as starting compounds, there are mentioned in particular: 2-methyl- 3 carboxylic acidamido-quinoxaline-di-N-oxide-(1.4), 2-methyl-3-carboxylic acidmethylamido quinoxaline-di- N oxide (1.4), 2,7-dimethyl-3-carboxylic acidmethylamido quinoxaline di N oxide (1.4), 2-methyl-3- carboxylic acidbutylamido 7 chloroquinoxaline di- N oxide (1.4), 2-methyl 3 carboxylic acidpyrrolidylamido 7 methoxy quinoxaline di N oxide- (1.4), 2 methyl 3 carboxylic acid piperidylamido- 7 ethoxy quinoxaline di N oxide (1.4), 2 methyl- 3 carboxylic acid B methoxy ethylamido quinoxaline di N oxide (1.4), 2 methyl 3 carboxylic aciddimethylamido quinoxaline
• Suitable halogenating agents are sulphuryl chloride, bromine in gasous or liquid form or dissolved in an organic diluent and, preferably, chlorine.
• halogenating agent About one to about two moles of halogenating agent are used per mole of 2-methyl-3-carboxylic acid amidoquinoxaline-1,4-di-N-oxide.
• Suitable diluents are formic acid, glacial acetic acid and chlorinated hydrocarbons, e.g., methylene chloride, chloroform, carbon tetrachloride, perchloroethylene, chlorobenzene.
• the halogenations are carried out in the temperature range of about 20 C. to about 120 C., preferably 60 C. to 100 C.
• the new compounds of the invention are yellow crystalline substances, which can be isolated in the usual manner and, if necessary, be purified.
• the antibacterial activity of the compounds of the present invention has been demonstrated both in vitro and in vivo and the compounds of the present invention have, in such tests, shown utility upon both subcutaneous as well as oral administration against acute bacterial infections.
• the compounds are effective against a range of both gram positive and gram negative bacteria.
• the general dosage ranges of the compounds of the present invention are from about mg. to about 300 mg.
• the compounds of the present invention may be used either as such or may be administered in combination with known pharmaceutically acceptable carriers and diluents.
• Suitable as administration forms in combination with various inert carriers and diluents for the compounds of the present invention are tablets, capsules, powders, sprays, elixirs, aqueous suspensions, injectable solutions, syrups and the like.
• the carriers and diluents also include fillers and sterile aqueous media, as well as non-toxic organic solvents and other suitable pharmaceutical vehicles well known by those in the art.
• tablets, capsules or other forms used for oral administration may be provided with a sweetening additive or other '4 suitable flavoring substance.
• the compounds of the present invention, which is the active ingredient in such a pharmaceutical composition should be present in a concentration of from about 0.5 to about by weight of the total composition.-
• tablets may also contain such known additives as sodium citrate, calcium carbonate, 'dicalcium phosphate, together with various adjuvants 'such as starch, preferably potato starch, and the like, and binders such as polyvinylpyrrolidine, gelatin and the like, lubricants such as magnesium stearate, sodium lauryl sulphate and talc' may also be used for tabletmaking.
• suitable substances to improve the taste, dyestuffs, emulsifiers and/ or diluents such as water, ethanol, propylene glycol, glycerol and the like, may be added.
• the compound of the present invention may be combined with sesame oil or arachis oil or aqueous propylene glycol or N-dimethyl formamide may be used, as well as sterile aqueous solutions when water soluble compounds are utilized. If necessary, such aqueous solutions can be buffered in known and customary manner and the liquid diluents should be rendered isotonic beforehand by the addition of the requisite amount of salt or glucose. Such aqueous solutions are particularly suitable for intravenous, intramuscular and intraperitoneal injections. Sterile aqueous media may be prepared in manners per se known in the art.
• the bacteria used for infections were E. coli, Klebsiella, Staphylococcus aureus, Diplococcus pneumoniae or Streptoccus pyogenes, Proteus mirabilic and Pseudomonas aeruginosa.
• the ED of the most effective compounds (e.g., 1, 16, 4, 11, 2) against E. coli C lies, in the case of administration in one dose, orally or subcutaneously, between 5 mg./kg. and 100 mg./kg.
• the DL lies in the dosage range of about 400 mg./ kg. to about 1500 mg./kg. after oral administration in one dose to mice.
• the substances are thus relatively non-toxic since the relatively less well tolerated ones are distinguished by higher effectiveness and are, therefore, applied only in low dosage. Also in the case of treatment of rats with 60 mg./kg. orally twice daily over two weeks, the substances were well tolerated.
• dosages of 2x 15 mg./kg. daily, i.e., 15 mg./kg. twice a day, over 7-l0 days were applied with success and were tolerated well.
• the substances act bacteriostatically and bactericidally.
• the new compounds are also effective against Mycoplasma infections in the in nitro test, amountsof about 5 to about 50 7 per ml. being used.
• H 100 Severe pyelonephrltes In vitro inhibition values-Minimum inhibition concentration in ugJml. nutrient maximni Example 1. 2 3 4 5 6 8 9 11 12 14 15 16 3-12 12-25 10-100 5-100 10-100 10 100 5-100 10-100 100 100 100 100 2 12-100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 10 3 12-25 10 10 100 10 100 10 100 10 6-100 100 100 10 1-6 12-50 10-100 10-100 100 10-100 100 10-100 3-100 100 5 6 6-25: 5 10 10 10 100 10 10, 10 5 l0 1 10 10 100 100 100 100 100 10 Pneumococeus-. -50 Salmonella 0. 5 Noisseria 0.5 Corynebacterium dipht. 1
• the new 2-halomethyI-3-carboxy1ic acid amido-quinoxaline-di-N-oxides-(IA) also show (same generaldosage latitude as stated above) efie'ctiveness against amoebae and flagellates (E.histolytica, Trichomonas vaginalis, Lamblia muris in vitro as well as in vivo tests on animals e.g. mice, rats, golden hamsters).
• the compounds of the present invention may also be produced by oxidizing quinoxalines of the formula: 1
• R R and R are as above defined.
• Hydrogen peroxide in the presence of glacial acetic acid or acetic anhydride is a preferred oxidizing agent.
• The-oxidation can also be carried out with organic peracids, such as peracetic acid, perbenzoic acid, monoperphthalic acid and the like.
• organic peracids such as peracetic acid, perbenzoic acid, monoperphthalic acid and the like.
• the present invention also includes pharmaceutical compositions containing-at least one compound of the present invention in combination or admixture with a solid or liquid diluent or carrier,';as well as methods of treating bacterial infections.
• the present invention also includes unit dosage forms comprising at least one compound of the present invention either alone or in ad mixture or combination with a solid or liquid diluent or 1 1 carrier.
• the compound may be suitably enveloped by a protective covering containing the compound itself and, if used, a diluent or carrier.
• medicament in dosage unit form means a medicament as defined above in the form of discrete portions each containing a unit dose, or a multiple or sub-multiple of a unit dose of the active compound or compounds.
• Such portions may, for example, be in monolithic coherent form, such as tablets, suppositories, pills or drages; in wrapped or concealed form, such as wrapped powders, cachets, sachets, or capsules; in ampoules, either free or as a sterile solution suitable for parenteral injection; or in any other form known to the art.
• R is hydrogen, lower alkyl of 1 to 4 carbon atoms, lower alkoxy of 1 to 4 carbon atoms or chlorine
• R is hydrogen, straight or branched chain alkyl of l to 12 carbon atoms or straight or branched chain alkyl of l to 12 carbon atoms substituted by hydroxy, lower alkox'y of 1 to 4 carbon atoms, acyloxy of 1 to 4 carbon atoms in the alkyl portion, monoalkylamino of 1 to 4 carbon atoms in the alkyl portion or dialkylamino of l to 4 carbon atoms in each alkyl portion,
• R is hydrogen, straight or branched chain alkyl of l to 12 carbon atoms, straight or branched chain alkyl of 1 to 12 carbon atoms substituted by hydroxy, lower alkoxy of 1 to 4 carbon atoms, acyloxy of 1 to 4 carbon atoms in the alkyl portion, monoalkylamino of 1 to 4 carbon atoms in the alkyl portion or dialkylamino of 1 to 4 carbon atoms in each alkyl portion, or when R is hydrogen, cyclohexyl, or
• Hal is chlorine or bromine.
• R and R alkyl moieties are of 1 to 6 carbon atoms.
• a process for the production of a compound of claim 1 which comprises reacting a compound of the formula:
• R is hydrogen, lower alkyl of 1 to 4 carbon atoms, lower alkoxy of 1 to 4 carbon atoms or chlorine,
• R is hydrogen, straight or branched chain alkyl of 1 to 12 carbon atoms or straight or branched chain alkyl of 1 to 12 carbon atoms substituted by hydroxy, lower al koxy of 1 to 4 carbon atoms, acyloxy of 1 to 4 carbon atoms in the alkyl portion, monoalkylamino of 1 to 4 carbon atoms in each alkyl portion or dialkylamino of 1 to 4 carbon atoms in each alkyl portion,
• R is hydrogen, straight or branched chain alkyl of l to 12 carbon atoms, straight or branched chain alkyl of 1 to 12 carbon atoms substituted by hydroxy, lower al-koxy of 1 to 4 carbon atoms, acyloxy of 1 to 4 carbon atoms in the alkyl portion, monoalkylamino of 1 to 4 carbon atoms in the alkyl portion or dialkylamino of 1 to 4 carbon atoms in each alkyl portion, or when R is hydrogen, cyclohexyl, or
• R and 'R together with the amide nitrogen atom form a pyrrolidyl or piperidyl ring, with a halogenating agent selected from the group consisting of sulphuryl, chloride and bromine in gaseous form, liquid form or dissolved in an organic diluent at a temperature of from about 20 C. to about 120 C.,

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Solid-Fuel Combustion (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=7106504

Family Applications (2)

Family Applications After (1)

Country Status (14)

Cited By (4)

Families Citing this family (3)

• 1967
  • 1967-10-04 DE DE1670937A patent/DE1670937C3/de not_active Expired
• 1968
  • 1968-09-15 IL IL6830706A patent/IL30706A/en unknown
  • 1968-09-16 CH CH1387268A patent/CH512499A/de not_active IP Right Cessation
  • 1968-09-27 NO NO3843/68A patent/NO122018B/no unknown
  • 1968-10-01 SE SE13257/68A patent/SE344329B/xx unknown
  • 1968-10-02 YU YU2295/68A patent/YU32936B/xx unknown
  • 1968-10-02 US US764610A patent/US3557109A/en not_active Expired - Lifetime
  • 1968-10-03 DK DK478568AA patent/DK118288B/da unknown
  • 1968-10-03 GB GB47012/68A patent/GB1188249A/en not_active Expired
  • 1968-10-03 AT AT964268A patent/AT284128B/de not_active IP Right Cessation
  • 1968-10-04 ES ES358796A patent/ES358796A1/es not_active Expired
  • 1968-10-04 NL NL6814256.A patent/NL157900B/xx unknown
  • 1968-10-04 FI FI682813A patent/FI49718C/fi active
  • 1968-10-04 FR FR1597551D patent/FR1597551A/fr not_active Expired
  • 1968-12-30 FR FR181599A patent/FR8125M/fr not_active Expired
• 1969
  • 1969-11-12 US US00871269A patent/US3754087A/en not_active Expired - Lifetime

Also Published As

Similar Documents